Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Melanocortin-4 (MC4) receptor agonist (anti-obesity agent)

Setmelanotide

IMCIVREE

Dosage form
Tablet
Available strengths
10 mg/mL
Drug class
Melanocortin-4 (MC4) receptor agonist (anti-obesity agent)
Common brand
IMCIVREE

Clinical overview. Setmelanotide is a once-daily subcutaneous injection (brand name IMCIVREE) that activates the MC4 receptor to support weight management in adults and children 6 years and older with obesity caused by Bardet-Biedl syndrome or confirmed POMC, PCSK1, or LEPR gene deficiency. It commonly causes injection site reactions, skin darkening, and gastrointestinal upset, and can cause depression, suicidal thoughts, or prolonged erections that require urgent medical attention. It is not recommended during pregnancy or breastfeeding and treatment is stopped if adequate weight loss is not seen after a defined evaluation period.

Indication

Common therapeutic uses

  • Setmelanotide is used for weight management in adults and children 6 years of age and older with obesity caused by Bardet-Biedl syndrome (BBS).
  • Setmelanotide is used for weight management in adults and children 6 years of age and older with obesity caused by genetically confirmed biallelic deficiency of the POMC, PCSK1, or LEPR genes.
  • Setmelanotide is not expected to work, and is not indicated, for obesity caused by gene variants classified as benign, or for other forms of obesity not related to these specific genetic causes, including general (polygenic) obesity.

Pregnancy

Risk assessment and monitoring considerations

  • There are no data on setmelanotide use in pregnant women, and it is not recommended during pregnancy or while trying to conceive.
  • Weight loss during pregnancy may harm the developing baby.
  • IMCIVREE contains the preservative benzyl alcohol; although this is broken down quickly by a pregnant woman so fetal exposure is unlikely, its breakdown product can build up over time and cause metabolic acidosis if used intravenously in vulnerable patients.
  • Animal studies showed decreased maternal food intake and related effects on the developing fetus in pregnant rabbits, though setmelanotide itself was not found to cause birth defects in two animal species.

Breastfeeding

Infant exposure considerations

  • Treatment with setmelanotide is not recommended while breastfeeding.
  • It is not known whether setmelanotide passes into human breast milk, but it was found in the milk of nursing rats, so it is likely present in human milk as well.
  • Benzyl alcohol, a preservative in IMCIVREE, is broken down quickly by a breastfeeding woman, making infant exposure through milk unlikely, though caution is still advised.

Geriatrics

Dosing and tolerability considerations

  • Clinical studies of setmelanotide did not include patients 65 years of age or older, so it is not known whether older adults respond differently.

Pediatrics

Use in children and adolescents

  • Setmelanotide is approved for children 6 to 17 years of age; safety and effectiveness have not been established in children younger than 6.
  • IMCIVREE is not approved for use in neonates or infants, since it contains the preservative benzyl alcohol, which has been linked to serious and fatal reactions, including "gasping syndrome," in newborns and low birth weight infants.

Dosage & Administration

Practical dosing and administration

  • In adults, the starting dose is 1 mg injected under the skin once daily for 2 weeks, then increased by 0.5 mg daily every 2 weeks as tolerated, up to a maximum of 3 mg daily.
  • In children 6 to 17 years of age, the starting dose is 0.5 mg injected under the skin once daily for 2 weeks, then increased by 0.5 mg daily every 2 weeks as tolerated, up to a maximum of 2 mg daily.
  • If the starting dose is not tolerated in either age group, setmelanotide should be discontinued.
  • No dose adjustment is needed for mild or moderate kidney impairment; for severe kidney impairment, a lower starting dose and maximum dose apply in adults and children 12 years and older, and use is not recommended in children 6 to 11 years old with severe kidney impairment or in anyone with end-stage kidney disease.
  • Setmelanotide is not recommended in patients with any degree of liver impairment, since it has not been studied in this population.
  • In patients with Bardet-Biedl syndrome, weight loss is assessed after 22 weeks of treatment; in patients with POMC, PCSK1, or LEPR deficiency, weight loss is assessed after 12 to 16 weeks. Treatment should be stopped if the patient has not achieved a defined minimum reduction in baseline body weight (or in baseline BMI for patients with continued growth potential), since continued treatment is unlikely to provide meaningful benefit.
  • Setmelanotide is injected once daily, at the start of the day, without regard to meals.
  • If a dose is missed, the regular once-daily schedule should simply resume with the next scheduled dose.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Data on setmelanotide overdose are limited.
  • Symptoms of overdose are expected to resemble the adverse effects observed in clinical trials.
  • Management includes supportive treatment, such as monitoring heart rate and blood pressure, guided by the patient's clinical signs and symptoms.

Common side effects

Frequently reported tolerability concerns

  • Injection site reactions, such as redness, itching, swelling, pain, or bruising, are very common.
  • Skin darkening (hyperpigmentation) is very common.
  • Spontaneous erections in male patients are common.
  • Nausea is common.
  • Headache is common.
  • Diarrhea is common.
  • Abdominal pain is common.
  • Vomiting is common.
  • New moles (melanocytic nevi) are common.
  • Back pain is common.
  • Fatigue and weakness (asthenia) are common.
  • Dizziness may occur.
  • Dry mouth may occur.
  • Vertigo may occur.
  • Chills may occur.
  • Anxiety may occur.
  • Hair loss (alopecia) may occur.
  • Skin redness (erythema) or increased sweating (hyperhidrosis) may occur.
  • A raised, bumpy rash may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Depression and suicidal thoughts or behaviour can occur and have sometimes been serious; patients with a history of depression may be at higher risk.
  • Sexual arousal disturbances can occur, including erections lasting longer than 4 hours (priapism), which is a medical emergency.
  • Widespread skin darkening and darkening of existing moles can occur due to the drug's mechanism; new or changing moles should be examined regularly, and setmelanotide should not be used in patients with a personal or family history of melanoma or pre-melanoma skin lesions.
  • The preservative benzyl alcohol has been linked to serious and fatal reactions, including "gasping syndrome," in newborns and low birth weight infants; IMCIVREE is not approved for this population.
  • Seek urgent medical attention for an erection lasting more than 4 hours, new or worsening depression, or thoughts of self-harm.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with a personal or family history of depression, suicidal thoughts, or self-harm; monitor for new or worsening mood changes throughout treatment.
  • Do not use in patients with a personal or family history of melanoma or pre-melanoma skin lesions; a full skin examination is recommended before starting and periodically during treatment.
  • Use with caution in patients with severe kidney impairment, who require a reduced starting and maximum dose.
  • Use with caution in patients with any degree of liver impairment, since setmelanotide has not been studied in this population and is not recommended.
  • Not recommended during pregnancy or while breastfeeding.
  • Inform patients that spontaneous erections and other sexual side effects may occur, and instruct them to seek emergency care for an erection lasting more than 4 hours.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to setmelanotide or to any ingredient in the formulation.

Drug interactions

Clinically relevant combinations

  • No clinical drug interaction studies have been conducted with setmelanotide.
  • Setmelanotide has a low potential for interactions involving cytochrome P450 enzymes or drug transporters, but interactions with other drugs have not been formally established.

Food interactions

Meal-related administration

  • Setmelanotide is given by injection under the skin, so food does not affect its absorption; it is administered once daily at the start of the day without regard to meals.

Time of administration

Practical scheduling

  • Injected once daily, at the beginning of the day, without regard to meals.

Storage

Product handling

  • Store unopened vials refrigerated at 2°C to 8°C, in the original carton.
  • After removing from the refrigerator, vials may be kept at temperatures from refrigerated up to 30°C for up to 30 days.
  • Once a vial has been punctured (opened), discard it after 30 days, even if kept refrigerated.
  • Discard any vial stored above 30°C.

Patient take-away

Key counselling points for a quick closing summary

  • Setmelanotide (IMCIVREE) is a once-daily injectable medicine for weight management in specific genetic forms of obesity, including Bardet-Biedl syndrome and POMC, PCSK1, or LEPR deficiency.
  • Skin darkening and injection site reactions are very common and expected with treatment.
  • Your doctor will regularly examine your skin for new or changing moles, since darkening of moles can occur.
  • Watch for new or worsening depression or thoughts of self-harm, and seek urgent care for an erection lasting more than 4 hours.
  • Effective contraception and avoiding this medicine during pregnancy or breastfeeding is important, since weight loss and the drug itself may affect a developing baby.

References

Source material and product information

  1. Health Canada Product Monograph — Setmelanotide

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.